[EN] SULFONAMIDE DERIVATES AS NLRP3 INHIBITORS<br/>[FR] DÉRIVÉS DE SULFONAMIDE UTILISÉS EN TANT QU'INHIBITEURS DE NLRP3
申请人:INFLAZOME LTD
公开号:WO2019166633A1
公开(公告)日:2019-09-06
The present invention relates to compounds of formula (I) : (I) wherein Q is selected from O or S; R1 is an optionally substituted hydrocarbyl group which may optionally include one or more heteroatoms N, O or S in its carbon skeleton, provided that the hydrocarbyl group includes at least one heteroatom N, O or S in its carbon skeleton or is substituted with a substituent comprising at least one heteroatom N, O or S, and provided that the atom of R1 which is attached to the sulfur atom of the remainder of the molecule is not a ring atom of a cyclic group; R2 is an α,α'-substituted cyclic group which may optionally be further substituted; R3 and R4 are each independently hydrogen, halogen, -OH, -NH2, -CN, -R5, -OR5, -NHRs or -N(R5)2; or R3 and R4 together with the carbon atom to which they are attached may form a 3- to 7- membered saturated or unsaturated, optionally substituted cyclic group; and R5 is independently optionally substituted C1-C4 alkyl. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
本发明涉及以下式(I)的化合物:(I)其中Q从O或S中选择;R1是一个可选择取代的烃基,其在碳骨架中可能包含一个或多个杂原子N、O或S,前提是烃基在其碳骨架中至少包含一个杂原子N、O或S,或者被一个含有至少一个杂原子N、O或S的取代基所取代,并且前提是R1的原子与分子的其余部分的硫原子相连的原子不是一个环的原子;R2是一个α,α'-取代的环基,可选择进一步取代;R3和R4各自独立地是氢、卤素、-OH、-NH2、-CN、-R5、-OR5、-NHRs或-N(R5)2;或者R3和R4与它们连接的碳原子一起可以形成一个3-至7-成员的饱和或不饱和、可选择取代的环基;R5独立地是可选择取代的C1-C4烷基。本发明还涉及这些化合物的盐、溶剂合物和前药,包括这些化合物的药物组合物,以及这些化合物在治疗和预防医学障碍和疾病中的用途,尤其是通过抑制NLRP3。